Pharmacologically Protecting and Rescuing Synapses from Beta Amyloid by Raising Synaptic PSD-95


While the underlying cause of Alzheimer’s disease is unknown, evidence from human genetics and transgenic mouse studies implicate amyloid beta. This protein greatly impacts synapses—gaps between two neurons that serve as the sites of transmission of electrical or chemical information—leading to their inability to function normally. The Malinow laboratory seeks to leverage recent findings indicating that synapses can be protected from amyloid beta by increasing the amount of an important synaptic protein, PSD-95. This increase in PSD-95 at synapses can be achieved pharmacologically using drugs that are being developed for human use. These studies provide important pre-clinical data.

Funding to Date



Drug Discovery, Therapeutic Strategies, Therapeutic Strategies + Drug Discovery, Therapeutic Strategies and Drug Discovery


Roberto Malinow, M.D., Ph.D.